The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus

T Kraaij, SWA Kamerling, ENM de Rooij… - Journal of …, 2018 - Elsevier
Objective In systemic lupus erythematosus (SLE) patients, excessive formation of neutrophil
extracellular traps (NETs) is observed and their degradation is impaired. In vitro, immune …

Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results

T Kraaij, EJ Arends, LS van Dam… - Nephrology Dialysis …, 2021 - academic.oup.com
Abstract Background Anti-CD20 B-cell depletion has not shown superior efficacy to standard
immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial …

TAC-TIC use of tacrolimus-based regimens in lupus nephritis

T Kraaij, OW Bredewold, S Trompet… - Lupus science & …, 2016 - lupus.bmj.com
Current guidelines do not mention tacrolimus (TAC) as a treatment option and no consensus
has been reported on the role of TAC in lupus nephritis (LN). The present study aimed to …

[HTML][HTML] Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

JR van Leeuwen, OW Bredewold, LS van Dam… - Kidney international …, 2022 - Elsevier
Avacopan is a new, promising treatment for antineutrophil cytoplasmic antibody–associated
vasculitis (AAV) and can potentially, significantly reduce steroid use. There were 2 phase 2 …

[HTML][HTML] Cardiovascular risk following conversion to Belatacept from a calcineurin inhibitor in kidney transplant recipients: a randomized clinical trial

OW Bredewold, J Chan, M Svensson, A Bruchfeld… - Kidney medicine, 2023 - Elsevier
Rationale & Objective In kidney transplant recipients (KTRs), a belatacept-based
immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) …

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

E Dirikgil, JR van Leeuwen, LS van Dam… - BMJ open, 2022 - bmjopen.bmj.com
Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in
combination with steroids as remission induction therapy for patients with antineutrophil …

A case of mononucleosis infectiosa presenting with cholemic nephrosis

OW Bredewold, JW De Fijter… - Nephrology Dialysis …, 2011 - academic.oup.com
A 38-year-old male was admitted with fever, progressive jaundice, cervical
lymphadenopathy, hepatomegaly and acute oliguric renal failure. Epstein-Barr virus (EBV) …

[HTML][HTML] Protocol: ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial

E Dirikgil, JR van Leeuwen, LS van Dam… - BMJ Open, 2022 - ncbi.nlm.nih.gov
Introduction Both rituximab (RTX) and cyclophosphamide (CYC) are effectively used in
combination with steroids as remission induction therapy for patients with antineutrophil …

LBO2 Long-term renal and cardiovascular risks of tacrolimus in lupus nephritis patients

M van Schaik, OW Bredewold, M Priester, WM Michels… - 2024 - lupus.bmj.com
Objective Systemic lupus erythematosus is associated with an increased risk of
cardiovascular disease. Tacrolimus is a calcineurin inhibitor that finds its origin in solid …

Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial

OW Bredewold, J Chan, M Svensson, A Bruchfeld… - 2022 - researchsquare.com
In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is
associated with beneficial effects on cardiovascular (CV) risk factors compared with …